SI2089364T1 - Spojine piridinona - Google Patents
Spojine piridinonaInfo
- Publication number
- SI2089364T1 SI2089364T1 SI200731303T SI200731303T SI2089364T1 SI 2089364 T1 SI2089364 T1 SI 2089364T1 SI 200731303 T SI200731303 T SI 200731303T SI 200731303 T SI200731303 T SI 200731303T SI 2089364 T1 SI2089364 T1 SI 2089364T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyridinone compounds
- pyridinone
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85754006P | 2006-11-08 | 2006-11-08 | |
| PCT/US2007/084047 WO2008058229A1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
| EP07844974.1A EP2089364B1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2089364T1 true SI2089364T1 (sl) | 2013-10-30 |
Family
ID=39048786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731303T SI2089364T1 (sl) | 2006-11-08 | 2007-11-08 | Spojine piridinona |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7851489B2 (sl) |
| EP (1) | EP2089364B1 (sl) |
| JP (1) | JP5276005B2 (sl) |
| KR (1) | KR101390076B1 (sl) |
| CN (1) | CN101535264B (sl) |
| AR (1) | AR063628A1 (sl) |
| AU (1) | AU2007317296B2 (sl) |
| CA (1) | CA2669266C (sl) |
| CL (1) | CL2007003226A1 (sl) |
| DK (1) | DK2089364T3 (sl) |
| ES (1) | ES2424851T3 (sl) |
| HK (1) | HK1131608A1 (sl) |
| HR (1) | HRP20130626T1 (sl) |
| MX (1) | MX2009004699A (sl) |
| NO (1) | NO342395B1 (sl) |
| PE (1) | PE20081490A1 (sl) |
| PL (1) | PL2089364T3 (sl) |
| PT (1) | PT2089364E (sl) |
| SI (1) | SI2089364T1 (sl) |
| TW (1) | TWI409259B (sl) |
| WO (1) | WO2008058229A1 (sl) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531396T3 (es) | 2008-01-23 | 2015-03-13 | Bristol Myers Squibb Co | Proceso para preparar compuestos de piridinona |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| KR101897302B1 (ko) * | 2010-04-30 | 2018-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | Ｎ－（４－（２－아미노－３－클로로피리딘－４－일옥시）－３－플루오로페닐）－４－에톡시－１－（４－플루오로페닐）－２－옥소－１，２－디히드로피리딘－３－카르복스아미드를 포함하는 제약 조성물 |
| CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
| CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
| ES2923760T3 (es) | 2011-06-10 | 2022-09-30 | Merck Patent Gmbh | Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de BTK |
| RU2014125230A (ru) | 2011-11-22 | 2015-12-27 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность |
| US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
| US8969388B1 (en) | 2012-07-28 | 2015-03-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109890819B (zh) | 2016-06-20 | 2022-11-22 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
| EP3484866B1 (en) * | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| RU2769693C2 (ru) * | 2016-12-19 | 2022-04-05 | Новартис Аг | Новые производные пиколиновой кислоты и их применение в качестве промежуточных соединений |
| PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| EP3589286B1 (en) | 2017-03-02 | 2022-08-03 | ASLAN Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
| CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
| WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
| WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
| WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
| WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
| WO2019101178A1 (zh) | 2017-11-24 | 2019-05-31 | 南京明德新药研发股份有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| BR112020008663A2 (pt) | 2018-03-08 | 2020-10-06 | Wellmarker Bio Co., Ltd. | composto derivado de tienopiridina, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo |
| MX2020012045A (es) | 2018-05-11 | 2021-03-29 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de ligando 1 de muerte programada (pd-l1). |
| AU2019359036A1 (en) | 2018-10-09 | 2021-06-03 | Aslan Pharmaceuticals Pte Ltd | Malonate salt of varlitinib |
| CA3116418A1 (en) * | 2018-10-19 | 2020-04-23 | The University Of British Columbia | Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses |
| WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
| JP2022543250A (ja) | 2019-08-02 | 2022-10-11 | ウェルマーカー・バイオ・カンパニー・リミテッド | オキソ－ピリジン縮合環誘導体、およびそれを含む医薬組成物 |
| MX2022001671A (es) | 2019-08-09 | 2022-05-13 | Incyte Corp | Sales de un inhibidor de pd-1/pd-l1. |
| EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
| CN115003307A (zh) | 2020-02-06 | 2022-09-02 | 伟迈可生物有限公司 | 用于预防或治疗与kras突变相关的癌症的药物组合物 |
| JP2023516381A (ja) | 2020-03-03 | 2023-04-19 | ウェルマーカー・バイオ・カンパニー・リミテッド | Ｋｒａｓ変異および活性化ｒｏｎが存在する癌の予防または治療のための医薬組成物 |
| CN116390729A (zh) | 2020-05-18 | 2023-07-04 | 伟迈可生物有限公司 | 用于预防或治疗与ron突变相关的非小细胞肺癌的药物组合物及其使用方法 |
| CN116685324A (zh) | 2020-05-18 | 2023-09-01 | 伟迈可生物有限公司 | 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法 |
| EP4154892A4 (en) | 2020-05-18 | 2023-12-06 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTS AND METHOD USING SAME |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2022099071A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| WO2022169248A1 (ko) * | 2021-02-02 | 2022-08-11 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| WO2022270881A1 (ko) * | 2021-06-22 | 2022-12-29 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
| WO2024134517A1 (ko) * | 2022-12-23 | 2024-06-27 | 주식회사 엘지화학 | Ron 억제제로서 신규한 화합물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
| AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| EP1087937A1 (en) | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| AU780698B2 (en) | 1999-07-20 | 2005-04-14 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
| FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
| CA2468716A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| ES2505090T3 (es) | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101535264B (zh) | 2012-11-28 |
| US20080114033A1 (en) | 2008-05-15 |
| JP5276005B2 (ja) | 2013-08-28 |
| AR063628A1 (es) | 2009-02-04 |
| PT2089364E (pt) | 2013-08-26 |
| KR20090096423A (ko) | 2009-09-10 |
| US7851489B2 (en) | 2010-12-14 |
| HRP20130626T1 (en) | 2013-08-31 |
| WO2008058229A1 (en) | 2008-05-15 |
| PE20081490A1 (es) | 2008-10-30 |
| HK1131608A1 (en) | 2010-01-29 |
| EP2089364B1 (en) | 2013-06-12 |
| NO20091605L (no) | 2009-05-27 |
| CA2669266C (en) | 2014-04-29 |
| AU2007317296A1 (en) | 2008-05-15 |
| CA2669266A1 (en) | 2008-05-15 |
| KR101390076B1 (ko) | 2014-04-29 |
| DK2089364T3 (da) | 2013-09-02 |
| US20110052583A1 (en) | 2011-03-03 |
| ES2424851T3 (es) | 2013-10-09 |
| CN101535264A (zh) | 2009-09-16 |
| PL2089364T3 (pl) | 2013-11-29 |
| US8536200B2 (en) | 2013-09-17 |
| MX2009004699A (es) | 2009-05-15 |
| AU2007317296B2 (en) | 2012-07-05 |
| JP2010509362A (ja) | 2010-03-25 |
| TWI409259B (zh) | 2013-09-21 |
| CL2007003226A1 (es) | 2008-02-08 |
| EP2089364A1 (en) | 2009-08-19 |
| NO342395B1 (no) | 2018-05-14 |
| TW200829564A (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130626T1 (en) | Pyridinone compounds | |
| GB0602424D0 (en) | Compounds | |
| GB0602046D0 (en) | Compounds | |
| GB0606876D0 (en) | Compounds | |
| GB0605786D0 (en) | Compounds | |
| GB0607175D0 (en) | Compounds | |
| GB0605784D0 (en) | Compounds | |
| GB0605785D0 (en) | Compounds | |
| EP2082022A4 (en) | COMPOUNDS | |
| GB0606913D0 (en) | Compounds | |
| EP2004174A4 (en) | NAPHTHALENEDIONED COMPOUNDS | |
| GB0602042D0 (en) | Compounds | |
| EP1973905A4 (en) | COMPOUNDS | |
| AP2009004767A0 (en) | Cubstituted azolin-2-yl-amino compounds | |
| EP2016069A4 (en) | BISPYRIDINIUMVERBINDUNGEN | |
| GB0602560D0 (en) | Compounds | |
| GB0602412D0 (en) | Compounds | |
| GB0600427D0 (en) | Compounds | |
| GB0602559D0 (en) | Compounds | |
| GB0605827D0 (en) | Compounds | |
| GB0602558D0 (en) | Compounds | |
| GB0602451D0 (en) | Compounds | |
| GB0602134D0 (en) | Compounds | |
| GB0602853D0 (en) | Compounds | |
| GB0602856D0 (en) | Compounds |